L&C BIO Corrects Audit Report, Adjusts Financial Liability Valuation Loss to 85.7 Billion Won and Reports Consolidated Net Loss of 138.2 Billion Won

L&C BIO corrected its audit report on June 12, 2026, changing the basis from separate to consolidated financial statements.
The correction reduced the financial liability valuation loss from 110.3 billion won to 85.7 billion won, which is a non-cash loss with no actual cash outflow.
On a consolidated basis, total assets were 456.6 billion won, total liabilities 248.1 billion won, and total equity 208.5 billion won, with a net loss of 138.2 billion won compared to a net profit of 141.5 billion won in the prior year.
The loss before tax as a percentage of equity rose to 35.7% from 13.2% due to the inclusion of the financial liability valuation loss, while operating profit remained positive at 4.4 billion won.
No capital erosion ratio was disclosed, and separate equity of 113.3 billion won remained well above the capital stock of 12.4 billion won.
This filing is a correction of accounting standards and does not involve any shareholder return or capital changes.
[AI Summary]L&C BIO's audit correction involves a non-cash adjustment due to accounting standard changes, with limited impact on actual cash flow or capital soundness. The swing to a consolidated net loss is driven by the financial liability valuation loss, while operating profit stays positive, making the impact on investor sentiment neutral. The net loss expansion is a short-term concern but does not significantly impair fundamentals when excluding non-cash items.